Seres Therapeutics (NASDAQ:MCRB - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 7th. Analysts expect Seres Therapeutics to post earnings of ($0.03) per share and revenue of $10.00 million for the quarter.
Seres Therapeutics Stock Performance
Shares of Seres Therapeutics stock opened at $9.40 on Wednesday. Seres Therapeutics has a 52-week low of $7.18 and a 52-week high of $30.60. The business's 50 day simple moving average is $12.70 and its 200 day simple moving average is $15.09. The firm has a market cap of $81.95 million, a PE ratio of -40.87 and a beta of 2.54.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on MCRB shares. Chardan Capital restated a "buy" rating and issued a $25.00 price objective on shares of Seres Therapeutics in a report on Thursday, March 20th. The Goldman Sachs Group cut their target price on shares of Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating for the company in a research note on Friday, March 14th. Finally, StockNews.com raised shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Wednesday, April 23rd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Seres Therapeutics currently has an average rating of "Hold" and an average price target of $80.00.
View Our Latest Analysis on Seres Therapeutics
About Seres Therapeutics
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Seres Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Seres Therapeutics wasn't on the list.
While Seres Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
